Takeaways: Knight Therapeutics’ Canadian launch of WYNZORA strengthens its dermatology portfolio and marks the commercialization of a product it inherited through the Paladin acquisition. The launch a...
Takeaways: Slenyto gives Canadian clinicians a prescription, extended‑release melatonin specifically studied for children and teens (ages 2 to <18) with autism spectrum disorder and/or Smith‑Mageni...
